Skip to main content
Erschienen in: Cancer Causes & Control 5/2019

19.03.2019 | Original Paper

Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data

verfasst von: Dima Dandachi, Quinn T. Ostrom, Insun Chong, Jose A. Serpa, Thomas P. Giordano, Carol Kruchko, Jill S. Barnholtz-Sloan, Nathan Fowler, Rivka R. Colen, Fanny E. Morón

Erschienen in: Cancer Causes & Control | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Primary central nervous system lymphoma (PCNSL) in patients living with HIV (PLWH) is a distinct entity; however, the management is adopted from patients without HIV. The study aims to examine the differences in presentation, treatment, and outcomes of PCNSL patients with or without HIV.

Methods

We retrospectively compared the characteristics of 144 patients with PCNSL with and without HIV, and analyzed factors associated with overall and progression-free survival. Results were compared to the Central Brain Tumor Registry of the United States (CBTRUS) and the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) system.

Results

Among all patients with PCNSL, 19% had HIV. PLWH were younger (38 vs. 63 years; p < 0.01) and more likely to be African American (59% vs. 7%; p < 0.01) and male (74% vs. 49%; p = 0.02) than patients without HIV. PLWH were more likely to have multiple lesions (67% vs. 43%; p = 0.02), hemorrhage (59 vs. 37%; p = 0.03), and peripheral rim enhancement (57% vs. 7%; p < 0.01) on imaging; to receive palliative care (15% vs. 2%) or whole brain radiation (63% vs. 3%); and less likely to receive chemotherapy (22% vs. 95%) (p < 0.01). Twenty-four patients, none PLWH, underwent stem cell transplant. Not receiving transplant was an independent factor in mortality and disease progression. Our cohort of patients, compared to the national database, were younger (60 vs. 65 years), 58% were white vs. 75%, and had longer median overall survival 43 vs. 25 months.

Conclusion

Epidemiology, imaging, and treatment options for patients with PCNSL with and without HIV differ, but HIV was not an independent factor of mortality or disease progression. More efforts are needed to improve access to research and treatment options for PLWH with PCNSL.
Literatur
1.
Zurück zum Zitat O’Neill BP, Decker PA, Tieu C, Cerhan JR (2013) The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol 88:997–1000CrossRefPubMedPubMedCentral O’Neill BP, Decker PA, Tieu C, Cerhan JR (2013) The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol 88:997–1000CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Matinella A, Lanzafame M, Bonometti MA, Gajofatto A, Concia E, Vento S et al (2015) Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study. J Neurol 262:1317–1327CrossRefPubMed Matinella A, Lanzafame M, Bonometti MA, Gajofatto A, Concia E, Vento S et al (2015) Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study. J Neurol 262:1317–1327CrossRefPubMed
4.
Zurück zum Zitat Malikova H, Koubska E, Weichet J, Klener J, Rulseh A, Liscak R et al (2016) Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma? Cancer Imaging 16:40CrossRefPubMedPubMedCentral Malikova H, Koubska E, Weichet J, Klener J, Rulseh A, Liscak R et al (2016) Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma? Cancer Imaging 16:40CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Lloyd IE, Clement PW, Salzman KL, Jensen RL, Salama ME, Palmer CA (2015) An unusual and challenging case of HIV-associated primary CNS Lymphoma with Hodgkin-like morphology and HIV encephalitis. Diagn Pathol 10:152CrossRefPubMedPubMedCentral Lloyd IE, Clement PW, Salzman KL, Jensen RL, Salama ME, Palmer CA (2015) An unusual and challenging case of HIV-associated primary CNS Lymphoma with Hodgkin-like morphology and HIV encephalitis. Diagn Pathol 10:152CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS (2011) Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol 101:257–265CrossRefPubMed Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS (2011) Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol 101:257–265CrossRefPubMed
7.
Zurück zum Zitat Yanagisawa K, Tanuma J, Hagiwara S, Gatanaga H, Kikuchi Y, Oka S (2013) Epstein-Barr viral load in cerebrospinal fluid as a diagnostic marker of central nervous system involvement of AIDS-related lymphoma. Intern Med 52:955–959CrossRefPubMed Yanagisawa K, Tanuma J, Hagiwara S, Gatanaga H, Kikuchi Y, Oka S (2013) Epstein-Barr viral load in cerebrospinal fluid as a diagnostic marker of central nervous system involvement of AIDS-related lymphoma. Intern Med 52:955–959CrossRefPubMed
8.
Zurück zum Zitat Tang YZ, Booth TC, Bhogal P, Malhotra A, Wilhelm T (2011) Imaging of primary central nervous system lymphoma. Clin Radiol 66:768–777CrossRefPubMed Tang YZ, Booth TC, Bhogal P, Malhotra A, Wilhelm T (2011) Imaging of primary central nervous system lymphoma. Clin Radiol 66:768–777CrossRefPubMed
9.
Zurück zum Zitat Westwood TD, Hogan C, Julyan PJ, Coutts G, Bonington S, Carrington B et al (2013) Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients. Eur J Radiol 82:e374–e379CrossRefPubMed Westwood TD, Hogan C, Julyan PJ, Coutts G, Bonington S, Carrington B et al (2013) Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients. Eur J Radiol 82:e374–e379CrossRefPubMed
10.
Zurück zum Zitat Han CH, Batchelor TT (2017) Diagnosis and management of primary central nervous system lymphoma. Cancer 123:4314–4324CrossRefPubMed Han CH, Batchelor TT (2017) Diagnosis and management of primary central nervous system lymphoma. Cancer 123:4314–4324CrossRefPubMed
11.
Zurück zum Zitat Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266–272CrossRefPubMed Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266–272CrossRefPubMed
12.
Zurück zum Zitat Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105:1414–1418CrossRefPubMedPubMedCentral Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105:1414–1418CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Liu J, Wang Y, Liu Y, Liu Z, Cui Q, Ji N et al (2017) Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: analysis of 89 cases. Oncol Lett 14:5505–5512PubMedPubMedCentral Liu J, Wang Y, Liu Y, Liu Z, Cui Q, Ji N et al (2017) Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: analysis of 89 cases. Oncol Lett 14:5505–5512PubMedPubMedCentral
14.
Zurück zum Zitat Gopal S, Martin KE, Richards KL, Eron JJ (2012) Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000–2010. AIDS Res Hum Retroviruses 28:798–805CrossRefPubMedPubMedCentral Gopal S, Martin KE, Richards KL, Eron JJ (2012) Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000–2010. AIDS Res Hum Retroviruses 28:798–805CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Han CH, Batchelor TT (2017) Primary central nervous system lymphoma. Continuum 23(6, Neuro-oncology):1601–1618PubMed Han CH, Batchelor TT (2017) Primary central nervous system lymphoma. Continuum 23(6, Neuro-oncology):1601–1618PubMed
16.
Zurück zum Zitat Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B et al (2016) High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma: a randomized phase III trial (MATRix). BMC Cancer 16:282CrossRefPubMedPubMedCentral Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B et al (2016) High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma: a randomized phase III trial (MATRix). BMC Cancer 16:282CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Skiest DJ, Crosby C (2003) Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 17:1787–1793CrossRefPubMed Skiest DJ, Crosby C (2003) Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 17:1787–1793CrossRefPubMed
18.
Zurück zum Zitat Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N et al (2015) Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol 26:958–966CrossRefPubMedPubMedCentral Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N et al (2015) Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol 26:958–966CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Mounier N, Spina M, Gisselbrecht C (2007) Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol 136:685–698CrossRefPubMed Mounier N, Spina M, Gisselbrecht C (2007) Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol 136:685–698CrossRefPubMed
21.
Zurück zum Zitat Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C et al (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19:v1–v88CrossRefPubMedPubMedCentral Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C et al (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19:v1–v88CrossRefPubMedPubMedCentral
25.
27.
Zurück zum Zitat Haldorsen IS, Espeland A, Larsson EM (2011) Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 32:984–992CrossRefPubMedPubMedCentral Haldorsen IS, Espeland A, Larsson EM (2011) Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol 32:984–992CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Go JL, Lee SC, Kim PE (2006) Imaging of primary central nervous system lymphoma. Neurosurg Focus 21:E4CrossRefPubMed Go JL, Lee SC, Kim PE (2006) Imaging of primary central nervous system lymphoma. Neurosurg Focus 21:E4CrossRefPubMed
29.
Zurück zum Zitat Koeller KK, Smirniotopoulos JG, Jones RV (1997) Primary central nervous system lymphoma: radiologic-pathologic correlation. Radiographics 17:1497–1526CrossRefPubMed Koeller KK, Smirniotopoulos JG, Jones RV (1997) Primary central nervous system lymphoma: radiologic-pathologic correlation. Radiographics 17:1497–1526CrossRefPubMed
30.
Zurück zum Zitat DeFilipp Z, Li S, El-Jawahri A, Armand P, Nayak L, Wang N et al (2017) High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer 123:3073–3079CrossRefPubMed DeFilipp Z, Li S, El-Jawahri A, Armand P, Nayak L, Wang N et al (2017) High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer 123:3073–3079CrossRefPubMed
31.
Zurück zum Zitat Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U et al (2016) High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol 3:e388–e397CrossRefPubMed Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U et al (2016) High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol 3:e388–e397CrossRefPubMed
32.
Zurück zum Zitat Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G et al (2006) High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24:3865–3870CrossRefPubMed Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G et al (2006) High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24:3865–3870CrossRefPubMed
34.
Zurück zum Zitat Wolf T, Kiderlen T, Atta J, Stephan C, Kann G, Brodt HR et al (2014) Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation. Infection 42:445–447CrossRefPubMed Wolf T, Kiderlen T, Atta J, Stephan C, Kann G, Brodt HR et al (2014) Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation. Infection 42:445–447CrossRefPubMed
36.
Zurück zum Zitat Howlader N, Shiels MS, Mariotto AB, Engels EA (2016) Contributions of HIV to Non-Hodgkin Lymphoma Mortality Trends in the United States. Cancer Epidemiol Biomarkers Prev 25:1289–1296CrossRefPubMed Howlader N, Shiels MS, Mariotto AB, Engels EA (2016) Contributions of HIV to Non-Hodgkin Lymphoma Mortality Trends in the United States. Cancer Epidemiol Biomarkers Prev 25:1289–1296CrossRefPubMed
Metadaten
Titel
Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data
verfasst von
Dima Dandachi
Quinn T. Ostrom
Insun Chong
Jose A. Serpa
Thomas P. Giordano
Carol Kruchko
Jill S. Barnholtz-Sloan
Nathan Fowler
Rivka R. Colen
Fanny E. Morón
Publikationsdatum
19.03.2019
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 5/2019
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-019-01144-8

Weitere Artikel der Ausgabe 5/2019

Cancer Causes & Control 5/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.